Alert: Major Price Decline (5/28/20)-ZIOPHARM Oncology Inc (NASDAQ: ZIOP).


ZIOPHARM Oncology Inc (NASDAQ: ZIOP) stock suffered a major decline of -12.0% on 5/28/20. The shares closed at $3.07. Moreover, trading volume in this decline was unusually high at 152% of normal. The stock has been weak relative to the market over the last nine months but has risen 11.6% during the last week.


Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to fall short of the cost of capital, ZIOP is expected to be a major Value Eraser.

ZIOPHARM Oncology has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. ZIOPHARM Oncology has a poor Power Rating of 24 and a very low Appreciation Score of 3, producing the Lowest Value Trend Rating.

Rating Review

In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.

About John Lafferty 79010 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.